FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366991610> ?p ?o ?g. }

• W4366991610 endingPage "12298" @default.
• W4366991610 startingPage "12285" @default.
• W4366991610 abstract "Abstract Background Patterns of treatment failure and subsequent treatment in non‐small cell lung cancer (NSCLC) patients treated with osimertinib are scarcely known. We analyzed the disease progression during osimertinib treatment to identify potential treatment strategies. Methods We identified advanced NSCLC patients who commenced osimertinib treatment after progression on previous epidermal growth factor receptor (EGFR)‐tyrosine‐kinase inhibitor (TKI) from June 2014 to November 2018 from electronic records. Patients' tumor characteristics, efficacy outcomes, affected organs from radiology studies, and treatment modalities before and after osimertinib were analyzed. Results Eighty‐four patients were included. At osimertinib initiation, bone (50.0%) and brain (41.9%) were the commonest single metastatic sites, whereas thoracic involvement (73.3%) was more frequent than bone (27.4%) or brain (20.2%) metastasis during disease progression on osimertinib. Oligo‐progressive disease (PD) and central nervous system (CNS)‐sanctuary PD were observed in 15 (17.9%) and 3 (3.6%) patients, respectively. Most patients without brain metastasis (BM) at osimertinib initiation remained BM‐free (46/49, 93.9%), and 60% of patients (21/35) with pre‐existing BM showed intracranial disease control despite extracranial PD. The resistance mechanisms to osimertinib were explored in 23 patients (27.4%), and T790M‐loss was observed in 14 patients (60.9%) who had worse survival outcomes than those without T790M‐loss (progression‐free survival, 5.4 vs. 16.5 months, p = 0.02; overall survival, not reached, p = 0.03). Conclusion PD during osimertinib treatment occurred preferentially in the thorax and pre‐existing sites. Extracranial PD prevailed over intracranial PD regardless of baseline BM and prior brain radiation. These results support osimertinib's intracranial efficacy and may guide treatment strategies for EGFR‐ mutated NSCLC with BM." @default.
• W4366991610 created "2023-04-27" @default.
• W4366991610 creator A5004340711 @default.
• W4366991610 creator A5009145920 @default.
• W4366991610 creator A5023055777 @default.
• W4366991610 creator A5026667487 @default.
• W4366991610 creator A5053501652 @default.
• W4366991610 creator A5082220016 @default.
• W4366991610 date "2023-04-25" @default.
• W4366991610 modified "2023-10-14" @default.
• W4366991610 title "Dynamics of disease progression during treatment with Osimertinib in patients with <i>EGFR</i> T790M‐positive non‐small cell lung cancer" @default.
• W4366991610 cites W1177986414 @default.
• W4366991610 cites W1984269605 @default.
• W4366991610 cites W1994539763 @default.
• W4366991610 cites W2029679234 @default.
• W4366991610 cites W2041835001 @default.
• W4366991610 cites W2114932214 @default.
• W4366991610 cites W2135192471 @default.
• W4366991610 cites W2514197168 @default.
• W4366991610 cites W2536396512 @default.
• W4366991610 cites W2536769127 @default.
• W4366991610 cites W2560717039 @default.
• W4366991610 cites W2594811626 @default.
• W4366991610 cites W2601045707 @default.
• W4366991610 cites W2770828094 @default.
• W4366991610 cites W2772237551 @default.
• W4366991610 cites W2783955681 @default.
• W4366991610 cites W2797700531 @default.
• W4366991610 cites W2885289995 @default.
• W4366991610 cites W2891909134 @default.
• W4366991610 cites W2902378590 @default.
• W4366991610 cites W2902991043 @default.
• W4366991610 cites W2909352383 @default.
• W4366991610 cites W2915789858 @default.
• W4366991610 cites W2945297162 @default.
• W4366991610 cites W2951165708 @default.
• W4366991610 cites W2965979846 @default.
• W4366991610 cites W2973162399 @default.
• W4366991610 cites W3002380503 @default.
• W4366991610 cites W3131413306 @default.
• W4366991610 cites W4231096603 @default.
• W4366991610 cites W4366991610 @default.
• W4366991610 doi "https://doi.org/10.1002/cam4.5926" @default.
• W4366991610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37096765" @default.
• W4366991610 hasPublicationYear "2023" @default.
• W4366991610 type Work @default.
• W4366991610 citedByCount "1" @default.
• W4366991610 countsByYear W43669916102023 @default.
• W4366991610 crossrefType "journal-article" @default.
• W4366991610 hasAuthorship W4366991610A5004340711 @default.
• W4366991610 hasAuthorship W4366991610A5009145920 @default.
• W4366991610 hasAuthorship W4366991610A5023055777 @default.
• W4366991610 hasAuthorship W4366991610A5026667487 @default.
• W4366991610 hasAuthorship W4366991610A5053501652 @default.
• W4366991610 hasAuthorship W4366991610A5082220016 @default.
• W4366991610 hasBestOaLocation W43669916101 @default.
• W4366991610 hasConcept C121608353 @default.
• W4366991610 hasConcept C126322002 @default.
• W4366991610 hasConcept C143998085 @default.
• W4366991610 hasConcept C2776256026 @default.
• W4366991610 hasConcept C2777626846 @default.
• W4366991610 hasConcept C2777930144 @default.
• W4366991610 hasConcept C2778087573 @default.
• W4366991610 hasConcept C2778164965 @default.
• W4366991610 hasConcept C2779013556 @default.
• W4366991610 hasConcept C2779438470 @default.
• W4366991610 hasConcept C2780580887 @default.
• W4366991610 hasConcept C71924100 @default.
• W4366991610 hasConceptScore W4366991610C121608353 @default.
• W4366991610 hasConceptScore W4366991610C126322002 @default.
• W4366991610 hasConceptScore W4366991610C143998085 @default.
• W4366991610 hasConceptScore W4366991610C2776256026 @default.
• W4366991610 hasConceptScore W4366991610C2777626846 @default.
• W4366991610 hasConceptScore W4366991610C2777930144 @default.
• W4366991610 hasConceptScore W4366991610C2778087573 @default.
• W4366991610 hasConceptScore W4366991610C2778164965 @default.
• W4366991610 hasConceptScore W4366991610C2779013556 @default.
• W4366991610 hasConceptScore W4366991610C2779438470 @default.
• W4366991610 hasConceptScore W4366991610C2780580887 @default.
• W4366991610 hasConceptScore W4366991610C71924100 @default.
• W4366991610 hasFunder F4320310773 @default.
• W4366991610 hasIssue "11" @default.
• W4366991610 hasLocation W43669916101 @default.
• W4366991610 hasLocation W43669916102 @default.
• W4366991610 hasLocation W43669916103 @default.
• W4366991610 hasOpenAccess W4366991610 @default.
• W4366991610 hasPrimaryLocation W43669916101 @default.
• W4366991610 hasRelatedWork W2844135249 @default.
• W4366991610 hasRelatedWork W2921871143 @default.
• W4366991610 hasRelatedWork W2944067375 @default.
• W4366991610 hasRelatedWork W2956057931 @default.
• W4366991610 hasRelatedWork W3000070469 @default.
• W4366991610 hasRelatedWork W3036162643 @default.
• W4366991610 hasRelatedWork W3175026159 @default.
• W4366991610 hasRelatedWork W4210464383 @default.
• W4366991610 hasRelatedWork W4220695811 @default.
• W4366991610 hasRelatedWork W4307840104 @default.
• W4366991610 hasVolume "12" @default.

• next